Research Grade Danburstotug (HV974236)

Fiche technique Partager le produit Copier les informations

Prix(USD) : $

Spécification :

100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique

Aperçu

Numéro de catalogue

HV974236

Description

Danburstotug (HV974236) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Reactivité des espèces

Human

Applications

ELISA, Bioactivity: FACS, Functional assay, Research in vivo, WB

Espèce hôte

Human

Isotype

IgG1-lambda

Système d'expression

Mammalian Cells

Clonalité

Monoclonal

Applications testées

Cible

B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274

Niveau d'endotoxines

Please contact the lab for this information.

Pureté

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Numéro d'accès

Q9NZQ7

Forme

Liquid

Tampon de stockage

0.01M PBS, pH 7.4.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
WB	1:500-1:2000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Noms alternatifs

2307144-65-4

Contexte

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443

2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410

3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417

4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419

5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298

6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077

7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201

Note

For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Danburstotug.
Bioactivity

Detects recombinant PDL1 (Catalog No: HV974011) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-PDL1 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human PDL1 (Catalog No: HV974011)
Lane 2: Negative control